Recombinant antibodies: a natural partner in combinatorial antifungal therapy (Q35710169)

9 August 2017

1 reference

title

Recombinant antibodies: a natural partner in combinatorial antifungal therapy (English)

1 reference

9 August 2017

1 reference

Ruth C Matthews

1

1 reference

PubMed ID

15040939

9 August 2017

James P Burnie

series ordinal

2

1 reference

PubMed ID

15040939

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

9 August 2017

1 reference

9 August 2017

22

1 reference

9 August 2017

7

1 reference

9 August 2017

865-871

1 reference

Comparison of caspofungin and amphotericin B for invasive candidiasis

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Clinical relevance of antifungal resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Antifungal drug resistance of pathogenic fungi.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Candida and AIDS: evidence for protective antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Antibodies against Candida: potential therapeutics?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Immunoblot analysis of the serological response in systemic candidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

The Hsp90 of Candida albicans can confer Hsp90 functions in Saccharomyces cerevisiae: a potential model for the processes that generate immunogenic fragments of this molecular chaperone in C. albicans infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Detection of an antibody response in immunocompetent patients with systemic candidiasis or Candida albicans colonisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

The application of epitope mapping in the development of a new serological test for systemic candidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

HSP 90, yeasts andCorynebacterium jeikeium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Isolation and characterization of a recombinant heat shock protein of Aspergillus fumigatus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Immunogenicity and antigenicity of a Plasmodium falciparum protein fraction (90-110 kDa) able to protect squirrel monkeys against asexual blood stages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Over-expression of Saccharomyces cerevisiae hsp90 enhances the virulence of this yeast in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Characterisation and cellular localisation of the immunodominant 47-Kda antigen of Candida albicans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

The 86-kilodalton antigen from Schistosoma mansoni is a heat-shock protein homologous to yeast HSP-90.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Brugia malayi: the diagnostic potential of recombinant excretory/secretory antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

The genome of Trypanosoma cruzi contains a constitutively expressed, tandemly arranged multicopy gene homologous to a major heat shock protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Expression of a cDNA encoding a Toxoplasma gondii protein belonging to the heat-shock 90 family and analysis of its antigenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

A pharmacologic guide to the clinical use of amphotericin B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Antifungal susceptibility testing: practical aspects and current challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Interaction between the N-terminal and middle regions is essential for the in vivo function of HSP90 molecular chaperone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Cellular localization of steroid hormone-regulated proteins during sexual development in Achlya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

17-beta-estradiol upregulates the stress response in Candida albicans: implications for microbial virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Molecular cloning of sequences encoding the human heat-shock proteins and their expression during hyperthermia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Dynamic activation of endothelial nitric oxide synthase by Hsp90.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Gamma-globulin and acquired immunity to human malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Antibodies specific for heat shock proteins in human and murine malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Heat-shock mannoproteins as targets of secretory IgA in Candida albicans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Isotype can affect the fine specificity of an antibody for a polysaccharide antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

Synergistic effect of Candida albicans and Staphylococcus aureus on mouse mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

7 January 2021

Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

7 January 2021

Structure and regulation of the HSP90 gene from the pathogenic fungus Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

7 January 2021

Developmental changes in the expression of Leishmania chagasi gp63 and heat shock protein in a human macrophage cell line.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

7 January 2021

Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.032

7 January 2021

10.1016/J.VACCINE.2003.11.032

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

15040939